Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model

Gemma Gay-Jordi¹,², Eduard Guash²,³,⁴, Begoña Benito²,³,⁴, Josep Brugada²,³, Stanley Nattel⁴, Lluís Mont²,³, Anna Serrano-Mollar¹,²

¹Department of Experimental Pathology, Institut d’Investigacions Biomédiques de Barcelona (IIBB-CSIC), Barcelona, Catalonia, Spain, ²Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain, ³Cardiology Department, The Thorax Institute, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain, ⁴Research Center, Montreal Heart Institute and Université de Montréal, Montréal, Quebec, Canada

Abstract

Rationale: Recently it has been shown that long-term intensive exercise practice is able to induce myocardial fibrosis in an animal model. Angiotensin II is a profibrotic hormone that could be involved in the cardiac remodeling resulting from endurance exercise.

Objective: This study examined the antifibrotic effect of losartan, an angiotensin II type 1 receptor antagonist, in an animal model of heart fibrosis induced by long-term intense exercise.

Methods and Results: Male Wistar rats were randomly distributed into 4 experimental groups: Exercise, Exercise plus losartan, Sedentary and Sedentary plus losartan. Exercise groups were conditioned to run vigorously for 16 weeks. Losartan was orally administered daily before each training session (50 mg/kg/day). Time-matched sedentary rats served as controls. After euthanasia, heart hypertrophy was evaluated by histological studies; ventricular collagen deposition was quantified by histological and biochemical studies; and messenger RNA and protein expression of transforming growth factor-β1, fibronectin-1, matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1, procollagen-I and procollagen-III was evaluated in all 4 cardiac chambers. Daily intensive exercise caused hypertrophy in the left ventricular heart wall and originated collagen deposition in the right ventricle. Additionally long-term intensive exercise induced a significant increase in messenger RNA expression and protein synthesis of the major fibrotic markers in both atria and in the right ventricle. Losartan treatment was able to reduce all increases in messenger RNA expression and protein levels caused by exercise, although it could not completely reverse the heart hypertrophy.

Conclusions: Losartan treatment prevents the heart fibrosis induced by endurance exercise in training animals.

Introduction

In recent years, a growing concern has arisen from numerous observational studies reporting that long-term intense sport activity could be associated with an increased risk of cardiac arrhythmias [1–5]. In a previous study by our group we have demonstrated a profibrotic cardiac remodeling following long-term intensive exercise training in experimental animals, this could be the basis for an increased arrhythmogenicity in athletes [6]. In this respect, a well designed recently published study, relates the presence of myocardial fibrosis in veteran endurance athletes in the absence of any other cause [7]. The etiology and clinical significance of these findings have yet to be fully elucidated. Theres is therefore a need for better understanding of the biological process involved and of any upper limit above which intense exercise can be harmful to health as well as the possibility of taking action to avoid this damage.

Long-term exercise is associated with hemodynamic changes and alters the loading conditions of the heart, these changes have classically characterized the physiology of “athlete’s heart”. It is known that hemodynamic overload activates the renin-angiotensin system (RAS) in the heart [8,9]. Although RAS plays an important role in cardiovascular homeostasis by influencing vascular tone, fluid and electrolyte balance, experimental evidence suggests that RAS activation induces fibroblast proliferation and myocyte hypertrophy [10,11]. Angiotensin II (ANGII) is produced by proteolytic cleavage of its precursor angiotensin I by angiotensin converting enzyme (ACE). ANGII plays an important role in cardiovascular fibrogenesis [12] by acting as a potent growth factor and cytokine for vascular smooth muscle cells, cardiac myocytes and cardiac fibroblasts, via activation of the angiotensin type I receptor (AT1) [13,14].

Losartan is a selective AT1 receptor antagonist. It has been demonstrated that inhibition of cardiac RAS with ACE inhibitors
and/or ANGII receptor blockers improves left ventricle function, prevents geometric remodeling, and prolongs survival in several heart diseases, such as hypertension, heart failure, ischemic heart disease, and diabetes mellitus [15,16]. The antifibrotic effect of losartan has also been described in other fibrotic processes such as pulmonary fibrosis [17].

The main objective of this study was to evaluate the anti-fibrotic effect of losartan in an animal model of heart fibrosis induced by chronic endurance exercise. Our results showed that losartan was able to prevent the development of myocardial fibrosis caused by intense exercise.

Materials and Methods

The experimental design
This study conformed to European Community (Directive 86/609/EEC) and Spanish guidelines for the use of experimental animals and it was approved by the institutional committees of animal care and research. 24 pathogen-free, 4 week old, male Wistar rats, weighing 100–125 g at the beginning of experiments (Charles River Laboratories, France), were housed in a controlled environment (12 : 12-h light-dark cycle), and fed rodent chow (A04; Panlab, Barcelona, Spain) and tap water ad libitum.

Experimental groups. Animals were randomly distributed into four experimental groups:

Sedentary(n = 12)

Sedentary + losartan (Sedentary + LOS)(n = 12)

Exercise(n = 12)

Exercise + losartan (Exercise + LOS)(n = 12)

The exercise protocol was performed as in our previous study [6]. Briefly, exercise rats underwent a daily running session on a treadmill (Panlab, Barcelona, Spain) five days a week for 16 weeks. Losartan (50 mg/kg/day) was administered orally, every day at the same hour, starting in the first exercise session and continuing up to the end of the experiment. The drug was dissolved in a final volume of 1.5 ml of distilled water. Oral administration was selected as this is the usual method in a clinical setting. The first exercise session lasted for 10 min at 25 cm/s, and the duration and intensity were gradually increased reaching 60 min at 60 cm/s on the 10th day these levels were then maintained until the end of training. The animals were euthanized three days after the end of the training program to avoid any immediate responses. The hearts were quickly removed, weighed, dissected into left ventricle (LV), right ventricle (RV), left atrium (LA) and right atrium (RA); they were then frozen in liquid nitrogen for storage at −80°C until analyzed (n = 6, for each group) or fixed for histological studies (n = 6, for each group).

Cardiac hypertrophy
Cardiac hypertrophy was assessed by determining the heart-weight to body-weight ratio and by measuring the ventricular wall thickness at papillary muscle levels. To measure the wall thickness from RV free wall (RV FW), interventricular septum (IV), and LV free wall (LV FW), 12 measurements from each wall were taken per animal in heart paraffin sections using analySIS Image Processing software (Soft Imaging System GMBH, Germany) as previously described [6].

Histology and morphometry
For the histological studies, the heart was perfused with a fixative solution (10% neutral-buffered formalin) at a pressure of 80 cm H2O, immersed in the fixative for 12–24 h, and embedded in paraffin. Sections were cut at 4 μm thick serial sections and stained with Picrosirius red to identify connective tissue and collagen deposition. Additionally, sections from the RV were stained with picrosirius-red to quantify of collagen deposition using analySIS Image Processing software (Soft Imaging System GMBH, Germany) as previously described [6]. Perivascular collagen was excluded from this measurement.

mRNA analysis
Total RNA was extracted from 50 to 100 mg of a section of the LV, RV, LA and RA using Trizol® reagent (Invitrogen Corporation, CA, USA) according to the manufacturer’s protocol. RNA integrity and loading amounts were assessed by examining UV/VIS at multiple wave lengths following the ND-3300 user manual V2.5, instructions (ND-3300, NanoDrop Technologies, USA). Analysis of transforming growth factor-β1 (TGF-β1), fibronectin-1, metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinase 1 (TIMP-1), procollagen-1 (Proc-I) and procollagen-3 (Proc-III) mRNA expression was obtained by Real-Time PCR. One μg total mRNA was converted to cDNA with the iScript cDNA (Bio-Rad Laboratories, CA, USA), according to the manufacturer’s protocol. 100 ng of cDNA was amplified by the iCycler iQ™5 version 3.1 (Bio-Rad Laboratories, CA, USA) using Applied Biosystems (Applied Biosystems, CA, USA) TaqMan gene expression assays (Rn00572010-m1 for TGF-β1, Rn00569575-m1 for fibronectin-1, Rn02532334-s1 for MMP-2, Rn00387550-m1 for TIMP-1, Rn00802735-m1 for Proc-III, and Rn00437584-m1 for Proc-I).
for TIMP-1, Rn01526721-m1 for procollagen-1, Rn01437675-m1 for procollagen-3 and Rn00667869-m1 for actin, which was used as a housekeeping reference). Data was analyzed with the ΔCt method.

**SDS-PAGE and Western blot**

Protein samples were extracted using Nonidet P-40 buffer. SDS-PAGE was performed on 5%–13% acrylamide gels. Proteins were electrotransferred to nitrocellulose membrane and probed with primary antibodies. The antibodies used included mouse monoclonal anti-TGF-β1 (ab27969, dilution 1/2000), mouse monoclonal anti-MMP2 (ab7032, dilution 1/1000), rabbit polyclonal to TIMP1 (ab61224 dilution 1/1000), mouse monoclonal to collagen-I (ab6308 dilution 1/1000) (all of them acquired from Abcam plc, Cambridge, UK); rabbit polyclonal antifibronectin (BP8025, dilution 1/1000) (Acris Antibodies GmbH, Herford, Germany) and rabbit polyclonal to collagen-III (dilution 1/500) (Santa Cruz Biotechnology, Ca, USA), and mouse monoclonal anti-actin (dilution 1/500) (Chemicon-Millipore Co, MA, USA), which served as a housekeeping reference. The membranes were incubated with the corresponding peroxidase-conjugated secondary antibodies, washed, and then incubated with ECL reagents (GE Healthcare Europe GmbH; Freiburg; GE) before exposure to high-performance chemiluminescence films. Gels were calibrated using Bio-Rad standard proteins (Hercules, CA) with markers covering a 7–240 kDa range. Films were scanned by using image-editing software NIH ImageJ software for densitometric analysis of immunoreactive bands.

**Statistical analysis**

Data is expressed as mean ± SEM values with 95% confidence intervals. Statistical analysis was carried out by analysis of variance (ANOVA) followed by appropriate post-hoc tests, including Bonferroni correction and unpaired t-test. (GraphPad Software (ANOVA) followed by appropriate post-hoc tests, including Bonferroni correction and unpaired t-test. (GraphPad Software Inc, San Diego, CA, USA). Significance was accepted when p<0.05.

**Results**

**Cardiac hypertrophy**

Exercise causes a significant body weight loss in both exercise groups. Losartan treatment did not modify the body weight loss. Heart weight did not show any significant differences between all the study groups. However, the heart-weight-to-body-weight ratio was significantly different between exercise groups and sedentary groups. The body and heart weight, and the ratio between body and heart weight are summarized in Table 1.

Direct measurements of wall thickness confirmed significant increments in IV and LV FW in the exercised groups compared to their respective sedentary groups, exercise+LOS shows a reduction in the LV FW thickening compared to exercise group, although the exercise+LOS remained significantly increased relative to LOS alone. No significant differences were observed in RV FW thickness (Fig. 1B).

**Histopathology**

To further examine the effect of exercise heart serial sections were stained with Picrosirius red to identify collagen deposition, and examined by light microscopy. Diffuse interstitial collagen deposition associated with disturbances in myocardial architecture was observed only in the exercise group (Fig. 2A). Additionally, morphometric quantification in RV confirmed a significant increase in collagen deposition only in the exercise group. No differences in collagen density were observed in the exercise+LOS group. (Fig. 2B)

**mRNA analysis**

Messenger RNA (mRNA) expression of TGFβ-1, fibronectin-1, MMP-2, TIMP-1, procollagen-1 and procollagen-3 was measured in all cardiac chambers of rats in all the different groups under study. TGFβ-1 expression was significantly increased in the RA of exercise and exercise+LOS compared to its respective sedentary groups, although the increase observed in the exercise+LOS group were significantly reduced compared to that of the exercise group (Figure 3A). Furthermore, TGF-β1 expression was also significantly increased in the LA and RV in only the exercise group compared to the sedentary group, while exercise+LOS did not show any significant differences compared to its sedentary group (Figure 3A).

Fibronectin-1 expression was significantly increased in RA and RV of exercise and exercise+LOS, compared to its respective sedentary groups, although the increase observed by exercise+LOS was significantly reduced compared to the exercise group (Figure 3B). Fibronectin-1 expression was also increased in the LA in only the exercise group compared to the sedentary group, while exercise+LOS did not show any significant differences compared to its sedentary group.

Finally, MMP-2, TIMP-1, procollagen-I and procollagen-III mRNA expression was significantly increased in the RA, LA and RV only in the exercise group, while its expression in the exercise+LOS group was similar to that of the control groups (Figure 3C, 3D, 3E and 3F).

**Western blot analysis**

Alterations in protein expression corresponding to mRNA changes were assessed by Western blot analysis for TGF-β1, fibronectin-1, MMP-2, TIMP1, collagen-I, and collagen-III.

| Body Weight | Heart Weight | Heart Weight/Body Weight (×1000) |
|-------------|--------------|----------------------------------|
| Sedentary   | 414.8 ± 13.98| 1.027 ± 0.090                    | 0.00244 ± 0.00009               |
| Sedentary+LOS | 382.5 ± 17.97| 0.940 ± 0.090                    | 0.00245 ± 0.00025              |
| Exercise    | 357.1 ± 8.25*| 1.118 ± 0.050                    | 0.00308 ± 0.00006*             |
| Exercise+LOS| 339.7 ± 8.69†| 1.025 ± 0.042                    | 0.00312 ± 0.00004†             |

Groups: Sedentary; Exercise; Sedentary+LOS = sedentary plus losartan; Exercise+LOS = exercise plus losartan; BW = body weight; HW = heart weight; HW/BW = heart weight-to-body weight ratio. Data are mean ± SEM of 6 animals (sedentary and sedentary+LOS) and 6 animals (exercise and exercise+LOS).

*p<0.05 exercise group vs sedentary group and
†p<0.05 sedentary+LOS vs exercise+LOS.

doi:10.1371/journal.pone.0055427.t001
Finally, collagen-III protein levels showed an increase in the exercise group in RA, LA and RV, while the exercise+LOS group showed the same protein levels as the sedentary groups (Figure 4F). Overall these results confirm the development of significant changes in the extracellular matrix (ECM) changes after 16 weeks of intensive endurance exercise, with a clear fibrosis development in the RV but not the LV, while also confirming the effectiveness of losartan treatment in preventing this pathological remodeling.

**Discussion**

We have shown that losartan, a selective AT1 receptor antagonist, ameliorates experimental exercise-induced myocardial fibrosis. Our findings provide further evidence for the anti-fibrotic effect of losartan.

Chronic exercise induces hemodynamic changes and alters the loading conditions of the heart [6], thus generating structural cardiac adaptations that are considered physiological, (and commonly known as athlete's heart) [18]. Long-term volume and pressure overloads, caused by intense exercise, can induce cardiac maladaptive responses including remodeling and fibrosis, which ultimately lead to heart tissue dysfunction similar to that found in pathological conditions of chronic overload such as heart failure and hypertension [19,20]. Several studies with animal models of acute exercise have shown histological evidence of reactive scar tissue formation and elevation of necrosis and fibrosis markers immediately following intense exercise [21,22]. Furthermore, Lindsay et al have found biochemical evidence of myocardial fibrosis in veteran endurance athletes [23]. Also, in a previous animal model we have demonstrated the direct relationship between a long-term endurance exercise schedule and the development of myocardial fibrosis and increased arrhythmia inducibility [6]. In this study, the progressive alteration in ECM composition induced by exercise increased myocardial stiffness, promoted the development of diastolic dysfunction and became a potential substrate for the development of arrhythmias [6]. It is particularly noteworthy that our findings in an animal model were similar to those observed in a study on veteran endurance athletes [7].

The present results confirm that 16 weeks of endurance exercise training in rats promotes left ventricular hypertrophy [6]. Furthermore, exercised animals developed myocardial fibrosis and showed alterations in ECM protein synthesis in both atria and in the right ventricle, indicating that these changes could promote alterations in heart functionality [6]. Therefore, ameliorating and preventing myocardial fibrosis would be very important in the management of future cardiovascular events [24,25]. ANGII is a powerful stimulus for progressive cardiac remodeling and plays a significant role in promoting myocardial fibrosis [26,27]. AT1 receptor antagonists have antifibrotic and anti-growth effects on the myocardium in experimental settings [28,29]. It has been reported that circulating ANG II plays a central role in the progression of myocardial fibrosis and hypertrophy in hypertensive patients [30,31].

As described in with previous works [6,32], our results also showed an increased cardiac mass and left ventricular hypertrophy, reflecting the enlargement of the left ventricular cavity that following long-term endurance training and that is considered typical of the athlete’s heart [18]. Left ventricular hypertrophy as detected by echocardiogram is an independent predictor of morbidity and mortality in subjects with high blood pressure [33] and in the population at large [34]. In the literature, there are several studies evaluating the therapeutic benefits of ACE inhibitors or the intervention of AT1 antagonists in reducing left

![Figure 2. Assessment of right ventricle myocardial fibrosis.](image-url)
In agreement with these studies, our findings show that losartan treatment was able to partially prevent left ventricular hypertrophy in exercised animals. One interesting observation is the fact that the development of hypertrophy is observed in the LV, but the increases in both the expression and the synthesis of fibrotic markers are observed in the RA, LA and RV. This could be explained by the intrinsic features of these cavities, including their thinner walls, which could make them more susceptible to damage from heart volume and pressure overload induced by exercise. In contrast, the LV structure is thicker and responds to pressure and volume overload by increasing its thickness even further, thus demonstrating greater resistance to changes in the composition of the ECM. Cardiac remodeling in response to hemodynamic stress and/or injury includes changes in the cardiomyocyte compartment as well as the nonmyocyte compartment (endothelial cells, vascular smooth muscle cells, macrophages, and cardiac fibroblasts). Pathological changes in cardiac remodeling include myocyte hypertrophy, myocyte death, and dynamic changes in the interstitium. Interstitial changes involve qualitative and quantitative alterations in the fibrillar collagen network (composed mainly of types I and III fibrillar collagen), including changes in collagen cross-linking [37]. Collagen-I determines the stiffness of cardiac muscle, whereas collagen-III is more distensible. Thus, the ratio of collagen-I to collagen-III can be a marker of the ECM determinants of cardiac stiffness [38]. We observed a significant increase in the expression of fibrosis markers in the RA, LA, RV, and LV in the exercise group compared to the sedentary group. Losartan treatment was able to partially prevent this increase, suggesting a protective effect on cardiac remodeling.

Figure 3. mRNA expression of fibrosis markers in each of the four cardiac chambers. Results are expressed according to the ΔCt method, with exercise group values in reference to those of the sedentary group (ΔCt ± SEM). Data are means ± SEM of 4 animals (all groups). * p<0.05 sedentary vs exercise; $ p<0.05 sedentary+LOS vs exercise+LOS, and, # p<0.05 exercise vs exercise+LOS.

doi:10.1371/journal.pone.0055427.g003
增加胶原-I和III型胶原蛋白表达的在RV中，胶原-I表达增加是更明显的，表明长期的、强烈的运动可以增加心肌的硬度。Losartan治疗是能够阻止所有这些增加控制水平在这一动物模型，表明治疗的有益效果于模型心肌重排导致从激进的疾病。

在总结中，这项研究证明了Losartan对心脏治疗在运动动物预防心脏纤维化影响深远。

### References

1. La Gerche A, Prior DL (2007) Exercise—Is it possible to have too much of a good thing? Heart Lung Circ 16 Suppl 3: S102–S104.
2. Mont L, Tamborero D, Eloua R, Molina I, Coll-Vinent B, et al. (2008) Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace 10: 15–20.
3. Baldisseri S, Bausfeld U, Candinas R, Seifert B, Zuber M, et al. (2008) Simultaneous node and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J 29: 71–78.
4. Buffa A, Pelliccia A, Verdile L, Fernando F, Spataro A, et al. (2002) Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol 40: 446–452.
5. Jiang Y, Qu P, Ding Y, Xia D, Wang H, et al. (2002) The relation between left ventricular mass index and left atrial size is independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace 10: 15–20.
6. Wilson MG, O’Hanlon R, Deighan A, Macmillan P, et al. (2011) Patterns of myocardial fibrosis in lifelong, veteran endurance athletes. J Appl Physiol Jun;110: 1622–1626.
7. Dahlöf B, Herlitz H, Aurell M, Hansson L (1992) Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens 5: 900–911.
8. Julius S (2007) Blood pressure lowering only or more? Has the jury reached its verdict? Am J Cardiol 100: 32J–37J.
9. Chun Y, Serfas RC, Mackey-Bojack SM, Kelly KL, Titus JL, et al. (2000) Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101: 1729–1735.
10. Querejeta R, Lopez B, Lopamur E, Artigas E, et al. (2004) Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110: 1263–1267.
11. Chen Y, Pessaux R, Mackay-Becky SM, Kelly KL, Titus JL, et al. (2000) Cardiac troponin T alterations in myocardium and serum of rats after stressful, prolonged intense exercise. J Appl Physiol 88: 1749–1753.
12. Verzosa RM, Mosqueda RA, Pesci H, Ramos OH, Morisco AS, et al. (2005) Early remodeling of rat cardiac muscle induced by swimming training. Braz J Med Biol Res 39: 621–627.
13. Lindsay MM, Dunn FG (2007) Biochemical evidence of myocardial fibrosis in veteran endurance athletes. Br J Sports Med 41: 447–452.
14. Ganau A, Deverus RB, Roman MJ, de Simone G, Pickering TG, et al. (1992) Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19: 1500–1538.
15. Li Z, Qiu P, Ding Y, Xiao D, Wang H, et al. (2002) The relation between left ventricular geometric patterns and left ventricular midwall mechanics in hypertensive patients. Hypertens Res 25: 191–195.
16. Weber KT (1997) Extracellular matrix remodeling in heart failure: a role for the novel angiotensin II generation. Circulation 96: 4065–4082.
17. Weber KT, Brillia CG (1991) Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849–1865.
18. Wu L, Iwai M, Nakagami H, Chen R, Suzuki JA, et al. (2002) Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arterioscler Thromb Vasc Biol 22: 49–54.
19. Molina-Molina M, Serrano-Mollari A, Balbena O, Fernandez-Zahaleg I, Closa D, et al. (2006) Losartan attenuates blemycin-induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax 61: 604–610.
20. Sadoshima J, Inoue S (1993) Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413–423.
31. Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT (1996) Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 154: 171–178.
32. Taniike M, Yamaguchi O, Tsujimoto I, Hikoso S, Takeda T, et al. (2008) Apoptosis signal-regulating kinase 1/p38 signaling pathway negatively regulates physiological hypertrophy. Circulation 117: 545–552.
33. Casale PN, Devereux RB, Millaert M, Zullo G, Harshfield GA, et al. (1986) Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105: 173–178.
34. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561–1566.
35. Avanza AC, Mansur Jr AP, Ramires JA (2009) Efficacy of exercise, Losartan, enalapril, atenolol and rilmenidine in subjects with blood pressure hyperreactivity at treadmill stress test and left ventricular hypertrophy. J Hum Hypertens 23: 259–266.
36. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003.
37. Chen K, Mehta JL, Li D, Joseph L, Joseph J (2008) Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 95: 1167–1173.
38. Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, et al. (1997) Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 96: 1991–1998.
39. Yoshiji H, Kuriyama S, Fukui H (2007) Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 22 Suppl 1: S93–S95.
40. Petrov VV, Fagard RH, Lijnen PJ (2002) Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39: 258–263.
41. Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145–2154.
42. Whyte G, Sheppard M, George K, Shave R, Wilson MP, et al. (2008) Post-mortem evidence of idiopathic left ventricular hypertrophy and idiopathic interstitial myocardial fibrosis: is exercise the cause? Br J Sports Med 42: 304–305.